RT Journal Article SR Electronic T1 Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5295 OP 5303 DO 10.21873/anticanres.12856 VO 38 IS 9 A1 KAZUKI TAKADA A1 GOUJI TOYOKAWA A1 TETSUZO TAGAWA A1 MOTOTSUGU SHIMOKAWA A1 KENICHI KOHASHI A1 AKIRA HARO A1 ATSUSHI OSOEGAWA A1 YOSHINAO ODA A1 YOSHIHIKO MAEHARA YR 2018 UL http://ar.iiarjournals.org/content/38/9/5295.abstract AB Aim: A combination of immune-checkpoint inhibitors that target the programmed cell death 1 (PD1)/programmed cell-death ligand 1 (PDL1) pathway and indoleamine 2,3-dioxygenase 1 (IDO1) is a promising treatment for non-small-cell lung cancer. Herein, we investigated clinical features of IDO1+/PDL1+ primary lung adenocarcinoma. Materials and Methods: IDO1 and PDL1 expression in 388 resected primary lung adenocarcinoma samples was evaluated using immunohistochemistry, and the radiological features of patients with IDO1+/PDL1+ lung adenocarcinoma were analyzed. Results: Of 388 specimens, 229 (59.0%) were IDO1+, 131 (33.8%) were PDL1+, and 109 (28.1%) were IDO1+/PDL1+. In multivariate analysis, vascular convergence and the absence of surrounding ground glass opacity were significantly associated with IDO1+/PDL1+ tumors. Fisher's exact test showed high consolidation/tumor ratio was also significantly associated with IDO1+/PDL1+ tumors. Moreover, maximum standardized uptake in 18F-fluorodeoxyglucose positron-emission tomography/computed tomography was significantly higher in patients with IDO1+/PDL1+ tumors than in those with IDO1− or PDL1− tumors. Conclusion: IDO1/PDL1 co-expression was significantly related to radiological invasiveness and malignancy in lung adenocarcinoma. This study may help select patients likely to benefit from combination therapy using immune-checkpoint inhibitors.